Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Non-Current Debt (2016 - 2025)

Cytosorbents (CTSO) has disclosed Non-Current Debt for 9 consecutive years, with $14.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Debt rose 5.51% year-over-year to $14.6 million, compared with a TTM value of $14.6 million through Sep 2025, up 5.51%, and an annual FY2024 reading of $14.0 million, up 450.4% over the prior year.
  • Non-Current Debt was $14.6 million for Q3 2025 at Cytosorbents, up from $14.4 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $14.6 million in Q3 2025 and bottomed at $1.9 million in Q1 2024.
  • Average Non-Current Debt over 4 years is $9.4 million, with a median of $13.7 million recorded in 2024.
  • The sharpest move saw Non-Current Debt plummeted 49.14% in 2023, then surged 635.61% in 2025.
  • Year by year, Non-Current Debt stood at $5.0 million in 2022, then tumbled by 49.14% to $2.5 million in 2023, then soared by 450.4% to $14.0 million in 2024, then grew by 4.08% to $14.6 million in 2025.
  • Business Quant data shows Non-Current Debt for CTSO at $14.6 million in Q3 2025, $14.4 million in Q2 2025, and $14.2 million in Q1 2025.